Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Since the first discovery of an inverse correlation between high‐density lipoprotein‐cholesterol (HDL‐C) levels and coronary heart disease in the 1950s the life cycle of HDL, its role in atherosclerosis and the therapeutic modification of HDL‐C levels have been major research topics. The Framingham study and others that followed could show that HDL‐C is an independent cardiovascular risk factor and that the increase of HDL‐C of only 10 mg·L−1 leads to a risk reduction of 2–3%. While statin therapy and therefore low‐density lipoprotein‐cholesterol (LDL‐C) reduction could lower coronary heart disease considerably; cardiovascular morbidity and mortality still occur in a significant portion of subjects already receiving therapy. Therefore, new strategies and therapies are needed to further reduce the risk. Raising HDL‐C was thought to achieve this goal. However, established drug therapies resulting in substantial HDL‐C increase are scarce and their effect is controversial. Furthermore, it is becoming increasingly evident that HDL particle functionality is at least as important as HDL‐C levels since HDL particles not only promote reverse cholesterol transport from the periphery (mainly macrophages) to the liver but also exert pleiotropic effects on inflammation, haemostasis and apoptosis. This review deals with the biology of HDL particles, the established and future therapeutic options to increase HDL‐C and discusses the results and conclusions of the most important studies published in the last years. Finally, an outlook on future diagnostic tools and therapeutic opportunities regarding coronary artery disease is given.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162 · cited 3×
“The Framingham Study was the first to suggest that positively influencing HDL-C levels may lead to a decrease in cardiovascular mortality (Gordon et al., 1977).”
BackgroundEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 2×
“…I and II studies (Brousseau et al., 2004; Davidson et al., 2006), in the large-scale phase III study, ILLUMINATE, torcetrapib therapy led to an increase in all-cause mortality and cardiovascular events, although it was able to increase HDL-C by 72% and decrease LDL-C by 25% (Barter et al., 2007).”
BackgroundYusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. (2001) · Circulation · doi:10.1161/hc4601.099487 · Cited by 2,972
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 3×
“But studies examining the effect of fibrates on cardiovascular mortality yielded disappointing results (Keech et al., 2005; Abourbih et al., 2009; Ginsberg et al., 2010; Tenenbaum and Fisman, 2010).”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979 · cited 1×
“LDL-C was reduced by 42% and HDL-C increased by 26% (Brown et al., 2001).”
BackgroundFifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · cited 2×
“…clinical trial in 3906 patients with previous MI. Niacin was shown to decrease the British Journal of Pharmacology (2012) 167 1177–1194 1179 occurrence of MI at 6 years (The Coronary Drug Project Research Group, 1975) as well as total mortality at 15 years significantly (Canner et al., 1986).”
BackgroundLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · cited 1×
“Although the authors reported a significant regression of coronary atherosclerosis, it is noteworthy that this significance was only calculated within groups, without comparing the atheroma changes in the treated versus the placebo group (Nissen et al., 2003).”
BackgroundBlankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
The Framingham Study: The Epidemiology of Atherosclerotic Disease
Dawber, T. R. (1980) · Harvard University Press eBooks · doi:10.4159/harvard.9780674492097 · Cited by 1,454
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010 · cited 1×
“High-dose statins are even beneficial in patients with normal LDL-C levels at baseline (Ridker et al., 2009).”
BackgroundEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Plasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942 · cited 1×
“Furthermore, HDL particles isolated from atherosclerotic lesions were very similar to the ones isolated from CAD patients’ plasma (Vaisar et al., 2007).”
ResultTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 861
High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules
Cockerill, G. W., Rye, K.-A., Gamble, J. R., Vadas, M. A., & Barter, P. J. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.11.1987 · Cited by 783
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774 · cited 2×
“Despite promising results in phase I and II studies (Brousseau et al., 2004; Davidson et al., 2006), in the large-scale phase III study, ILLUMINATE, torcetrapib therapy led to an increase in all-cause mortality and cardiovascular events, although it was able to increase HDL-C by 72% and decrease LDL-C by 25% (Barter e…”
ResultSafety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749 · cited 1×
“The phase III study DEFINE will examine anacetrapib’s effect in patients with CAD or CAD risk equivalents on a background statin therapy (Cannon et al., 2009; 2010).”
BackgroundTardif, J.-C. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 726
Influence of nicotinic acid on serum cholesterol in man
Altschul, R., Hoffer, A., & Stephen, J. D. (1955) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(55)90070-9 · Cited by 724
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
Navab, M., Hama, S. Y., Anantharamaiah, G. M., Hassan, K., Hough, G. P., Watson, A. D., Reddy, S. T., Sevanian, A., Fonarow, G. C., & Fogelman, A. M. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33462-3 · Cited by 668
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
High density lipoprotein cholesterol and mortality. The Framingham Heart Study.
Wilson, P. W., Abbott, R. D., & Castelli, W. P. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.6.737 · Cited by 644
WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583
Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
CARLSON, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 581
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 556
Fayad, Z. A., Mani, V., Woodward, M., Kallend, D., Abt, M., Burgess, T., Fuster, V., Ballantyne, C. M., Stein, E. A., Tardif, J.-C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61383-4 · Cited by 538
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up
Cashin-Hemphill, L. (1990) · JAMA · doi:10.1001/jama.264.23.3013 · Cited by 493
Briel, M., Ferreira-Gonzalez, I., You, J. J., Karanicolas, P. J., Akl, E. A., Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., et al. (2009) · BMJ · doi:10.1136/bmj.b92 · Cited by 491 · cited 2×
“…One meta-regression analysis, studying the association between change in HDL-C levels and CAD morbidity and mortality could not even detect a significant reduction of CAD risk upon elevation of HDL-C levels while the reduction of LDL-C levels had significant beneficial effect (Briel et al., 2009).”
BackgroundBots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
HDL and the Inflammatory Response Induced by LDL-Derived Oxidized Phospholipids
Navab, M., Berliner, J. A., Subbanagounder, G., Hama, S., Lusis, A. J., Castellani, L. W., Reddy, S., Shih, D., Shi, W., Watson, A. D., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.4.481 · Cited by 442
Conlan, M. G., Folsom, A. R., Finch, A., Davis, C. E., Sorlie, P., Marcucci, G., Wu, K. K., & For the ARIC Study Investigators (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649589 · Cited by 439
Tall, A. R. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01898.x · Cited by 436
Air Force/Texas Coronary Atherosclerosis Prevention Study
佐々木, 淳. (2008) · Japanese journal of clinical medicine · Cited by 411
Sorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402 · cited 1×
“Niacin stimulated endothelial NO production, endothelial progenitor cellmediated endothelial repair and reduced superoxide production, all properties which are impaired in diabetics compared with healthy controls (Sorrentino et al., 2010).”
BackgroundNavab, M., Anantharamaiah, G. M., Hama, S., Garber, D. W., Chaddha, M., Hough, G., Lallone, R., & Fogelman, A. M. (2002) · Circulation · doi:10.1161/hc0302.103711 · Cited by 401
Shah, P. K., Yano, J., Reyes, O., Chyu, K.-Y., Kaul, S., Bisgaier, C. L., Drake, S., & Cercek, B. (2001) · Circulation · doi:10.1161/hc2501.092494 · Cited by 381
Ordovas, J. M., Cupples, L. A., Corella, D., Otvos, J. D., Osgood, D., Martinez, A., Lahoz, C., Coltell, O., Wilson, P. W. F., & Schaefer, E. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1323 · Cited by 379
Nofer, J.-R., Levkau, B., Wolinska, I., Junker, R., Fobker, M., von Eckardstein, A., Seedorf, U., & Assmann, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103782200 · Cited by 359
Risérus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., et al. (2008) · Diabetes · doi:10.2337/db07-1318 · Cited by 325
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Hama, S., Hough, G., Grijalva, V. R., Wagner, A. C., Frank, J. S., Datta, G., Garber, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134275.90823.87 · Cited by 323
Sirtori, C. R., Calabresi, L., Franceschini, G., Baldassarre, D., Amato, M., Johansson, J., Salvetti, M., Monteduro, C., Zulli, R., Muiesan, M. L., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1949 · Cited by 322
Oxidation of High Density Lipoproteins
Garner, B., Waldeck, A. R., Witting, P. K., Rye, K.-A., & Stocker, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6088 · Cited by 319
Rittershaus, C. W., Miller, D. P., Thomas, L. J., Picard, M. D., Honan, C. M., Emmett, C. D., Pettey, C. L., Adari, H., Hammond, R. A., Beattie, D. T., et al. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.9.2106 · Cited by 312
Taylor, A. J., Lee, H. J., & Sullenberger, L. E. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148508 · Cited by 304
Nicholls, S. J., Dusting, G. J., Cutri, B., Bao, S., Drummond, G. R., Rye, K.-A., & Barter, P. J. (2005) · Circulation · doi:10.1161/01.cir.0000159351.95399.50 · Cited by 295
Bloedon, L. T., Dunbar, R., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B. J., Movva, R., Navab, M., Fogelman, A. M., & Rader, D. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.p800003-jlr200 · Cited by 292
Oxidation of High Density Lipoproteins
Garner, B., Witting, P. K., Waldeck, A. R., Christison, J. K., Raftery, M., & Stocker, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6080 · Cited by 278
Bruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273 · cited 1×
“Unfortunately, due to lack of well-powered studies on niacin monotherapy, the effect of niacin alone could not be assessed (Bruckert et al., 2010).”
BackgroundUremia Alters HDL Composition and Function
Holzer, M., Birner-Gruenberger, R., Stojakovic, T., El-Gamal, D., Binder, V., Wadsack, C., Heinemann, A., & Marsche, G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111144 · Cited by 268
Beyond lipid lowering: the role of statins in vascular protection
Liao, J. K. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00195-x · Cited by 266
Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p002816 · Cited by 259 · cited 3×
“Referring to results from the VOYAGER meta-analysis, saying that the extent of HDL-C increase is dependent on HDL-C levels at baseline (low HDL-C levels are associated with a higher increase during statin treatment) the observations made in JUPITER could therefore lead to false conclusions (Barter et al., 2010).”
BackgroundResultInfluentialRidker, P. M., Genest, J., Boekholdt, S. M., Libby, P., Gotto, A. M., Nordestgaard, B. G., Mora, S., MacFadyen, J. G., Glynn, R. J., & Kastelein, J. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60713-1 · Cited by 256
Severity of coronary atherosclerosis related to lipoprotein concentration.
Jenkins, P. J., Harper, R. W., & Nestel, P. J. (1978) · BMJ · doi:10.1136/bmj.2.6134.388 · Cited by 255
Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A. H., Hague, W., Keech, A., Thompson, P., White, H., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 254
Beyond High-Density Lipoprotein Cholesterol Levels
deGoma, E. M., deGoma, R. L., & Rader, D. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.016 · Cited by 253
Shepherd, J., Packard, C. J., Patsch, J. R., Gotto, A. M., & Taunton, O. D. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109385 · Cited by 248
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Tenenbaum, A., Motro, M., & Fisman, E. Z. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-14 · Cited by 246 · cited 2×
“However, it seems as if the activation of PPARs and in particular the balance between PPAR-a and PPAR-g binding, is more delicate than expected (Nissen et al., 2005; Tenenbaum et al., 2005; Kendall et al., 2006; Zadelaar et al., 2006; Kim et al., 2008; Casimiro-Garcia et al., 2009; Henry et al., 2009; van der Hoorn et…”
BackgroundCockerill, G. W., Huehns, T. Y., Weerasinghe, A., Stocker, C., Lerch, P. G., Miller, N. E., & Haskard, D. O. (2001) · Circulation · doi:10.1161/01.cir.103.1.108 · Cited by 246
Bloomfield, D., Carlson, G. L., Sapre, A., Tribble, D., McKenney, J. M., Littlejohn, T. W., Sisk, C. M., Mitchel, Y., & Pasternak, R. C. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.09.022 · Cited by 243
Sugano, M., Makino, N., Sawada, S., Otsuka, S., Watanabe, M., Okamoto, H., Kamada, M., & Mizushima, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5033 · Cited by 241
Shah, P. K., Nilsson, J., Kaul, S., Fishbein, M. C., Ageland, H., Hamsten, A., Johansson, J., Karpe, F., & Cercek, B. (1998) · Circulation · doi:10.1161/01.cir.97.8.780 · Cited by 239
The key role of apolipoprotein E in atherosclerosis
Greenow, K., Pearce, N. J., & Ramji, D. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0631-3 · Cited by 237
Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 234
Griffin, J. H., Kojima, K., Banka, C. L., Curtiss, L. K., & Fernández, J. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5006 · Cited by 232
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 230
Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men
Lamarche, B., Uffelman, K. D., Carpentier, A., Cohn, J. S., Steiner, G., Barrett, P. H., & Lewis, G. F. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5286 · Cited by 229
Villines, T. C., Stanek, E. J., Devine, P. J., Turco, M., Miller, M., Weissman, N. J., Griffen, L., & Taylor, A. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.017 · Cited by 223 · cited 2×
“(Villines et al., 2010) The large-scale AIM-HIGH trial was scheduled to present further results regarding the effect of niacin plus statin on therapy of cardiovascular disease in 2012; however, the study was terminated prematurely due to a lack of effect (more on that in the conclusions section; Brown, 2005).”
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Vergeer, M., Holleboom, A. G., Kastelein, J. J. P., & Kuivenhoven, J. A. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r001610 · Cited by 220
Boekholdt, S. M., Kuivenhoven, J.-A., Wareham, N. J., Peters, R. J. G., Jukema, J. W., Luben, R., Bingham, S. A., Day, N. E., Kastelein, J. J. P., & Khaw, K.-T. (2004) · Circulation · doi:10.1161/01.cir.0000141730.65972.95 · Cited by 218
The health risks of smoking the framingham study: 34 years of follow-up
Freund, K. M., Belanger, A. J., D'Agostino, R. B., & Kannel, W. B. (1993) · Annals of Epidemiology · doi:10.1016/1047-2797(93)90070-k · Cited by 206
Henry, R. R., Lincoff, A. M., Mudaliar, S., Rabbia, M., Chognot, C., & Herz, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60870-9 · Cited by 205
HDL and ApoA Prevent Cell Death of Endothelial Cells Induced by Oxidized LDL
Suc, I., Escargueil-Blanc, I., Troly, M., Salvayre, R., & Nègre-Salvayre, A. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.10.2158 · Cited by 204
Sprecher, D. L., Massien, C., Pearce, G., Billin, A. N., Perlstein, I., Willson, T. M., Hassall, D. G., Ancellin, N., Patterson, S. D., Lobe, D. C., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252790.70572.0c · Cited by 201
Chiesa, G., Monteggia, E., Marchesi, M., Lorenzon, P., Laucello, M., Lorusso, V., Di Mario, C., Karvouni, E., Newton, R. S., Bisgaier, C. L., et al. (2002) · Circulation Research · doi:10.1161/01.res.0000018422.31717.ee · Cited by 194
Schwartz, G. G., Olsson, A. G., Ballantyne, C. M., Barter, P. J., Holme, I. M., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Shah, P. K., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.09.017 · Cited by 183
High-Density Lipoproteins Protect Endothelial Cells from Tumor Necrosis Factor-α-Induced Apoptosis
Sugano, M., Tsuchida, K., & Makino, N. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2877 · Cited by 181
Wójcicka, G., Jamróz-Wiśniewska, A., Horoszewicz, K., & Bełtowski, J. (2007) · PubMed · Cited by 179
Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells
Mackness, B., Hine, D., Liu, Y., Mastorikou, M., & Mackness, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.056 · Cited by 178
van der Hoorn, J. W. A., de Haan, W., Berbée, J. F. P., Havekes, L. M., Jukema, J. W., Rensen, P. C. N., & Princen, H. M. G. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.171363 · Cited by 173
Dysfunctional HDL as a Diagnostic and Therapeutic Target
Smith, J. D. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179226 · Cited by 170
Thiazolidinediones and Blood Lipids in Type 2 Diabetes
van Wijk, J. P. H., de Koning, E. J. P., Martens, E. P., & Rabelink, T. J. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000090521.25968.4d · Cited by 165
Varady, K. A., & Jones, P. J. H. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.8.1829 · Cited by 163
Tölle, M., Pawlak, A., Schuchardt, M., Kawamura, A., Tietge, U. J., Lorkowski, S., Keul, P., Assmann, G., Chun, J., Levkau, B., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.161042 · Cited by 156
Is raising HDL a futile strategy for atheroprotection?
JOY, T. R., & Hegele, R. A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2489 · Cited by 155
Kendall, D. M., Rubin, C. J., Mohideen, P., Ledeine, J.-M., Belder, R., Gross, J. L., Norwood, P. C., O’Mahony, M., Sall, K. N., Sloan, G., et al. (2006) · Diabetes Care · doi:10.2337/diacare.2951016 · Cited by 152
Baker, P. W., Rye, K.-A., Gamble, J. R., Vadas, M. A., & Barter, P. J. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33375-7 · Cited by 151
Nicotinic acid: an old drug with a promising future
Bodor, E. T., & Offermanns, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707528 · Cited by 150
The mechanism and mitigation of niacin-induced flushing
Kamanna, V. S., Ganji, S. H., & Kashyap, M. L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02099.x · Cited by 149
Brousseau, M. E., O’Connor, J. J., Ordovas, J. M., Collins, D., Otvos, J. D., Massov, T., McNamara, J. R., Rubins, H. B., Robins, S. J., & Schaefer, E. J. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000024566.57589.2e · Cited by 148
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Schoenhagen, P., Crowe, T., Kapadia, S., & Nissen, S. E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.040 · Cited by 147
COCKERILL, G. W., Saklatvala, J., Ridley, S. H., Yarwood, H., Miller, N. E., Oral, H. B., Nithyanathan, S., Taylor, G. W., & Haskard, D. O. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.4.910 · Cited by 142
Riemens, S. C., van Tol, A., Sluiter, W. J., & Dullaart, R. P. F. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00111-7 · Cited by 140
Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
Abourbih, S., Filion, K. B., Joseph, L., Schiffrin, E. L., Rinfret, S., Poirier, P., Pilote, L., Genest, J., & Eisenberg, M. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.030 · Cited by 139
Tölle, M., Huang, T., Schuchardt, M., Jankowski, V., Prüfer, N., Jankowski, J., Tietge, U. J. F., Zidek, W., & van der Giet, M. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs089 · Cited by 139
Saha, S. A., Kizhakepunnur, L. G., Bahekar, A., & Arora, R. R. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.011 · Cited by 137
Stein, E. A., Stroes, E. S. G., Steiner, G. A., Buckley, B. M., Capponi, A. M., Burgess, T., Niesor, E. J., Kallend, D. G., & Kastelein, J. J. P. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.061 · Cited by 136
Liver X receptors (LXR) as therapeutic targets in dyslipidemia
Bełtowski, J. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00062.x · Cited by 132
Nissen, S. E., Nicholls, S. J., Wolski, K., Howey, D. C., McErlean, E., Wang, M.-D., Gomez, E. V., & Russo, J. M. (2007) · JAMA · doi:10.1001/jama.297.12.1362 · Cited by 131
Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome
Green, P. S., Vaisar, T., Pennathur, S., Kulstad, J. J., Moore, A. B., Marcovina, S., Brunzell, J., Knopp, R. H., Zhao, X.-Q., & Heinecke, J. W. (2008) · Circulation · doi:10.1161/circulationaha.108.770669 · Cited by 130
Davidson, M. H., McKenney, J. M., Shear, C. L., & Revkin, J. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.067 · Cited by 129
Tenkanen, L., Mänttäri, M., Kovanen, P. T., Virkkunen, H., & Manninen, V. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.743 · Cited by 129
Favari, E., Lee, M., Calabresi, L., Franceschini, G., Zimetti, F., Bernini, F., & Kovanen, P. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312476200 · Cited by 123
High‐density lipoproteins, platelets and the pathogenesis of atherosclerosis
Nofer, J., Brodde, M. F., & Kehrel, B. E. (2010) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05377.x · Cited by 122
Tabet, F., Remaley, A. T., Segaliny, A. I., Millet, J., Yan, L., Nakhla, S., Barter, P. J., Rye, K.-A., & Lambert, G. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.200196 · Cited by 122
The versatility of HDL: a crucial anti‐inflammatory regulator
Säemann, M. D., Poglitsch, M., Kopecky, C., Haidinger, M., Hörl, W. H., & Weichhart, T. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02361.x · Cited by 120
On the mechanism for PPAR agonists to enhance ABCA1 gene expression
Ogata, M., Tsujita, M., Hossain, M. A., Akita, N., Gonzalez, F. J., Staels, B., Suzuki, S., Fukutomi, T., Kimura, G., & Yokoyama, S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.008 · Cited by 120
Synthetic LXR agonists increase LDL in CETP species
Groot, P. H. E., Pearce, N. J., Yates, J. W., Stocker, C., Sauermelch, C., Doe, C. P., Willette, R. N., Olzinski, A., Peters, T., d'Epagnier, D., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500116-jlr200 · Cited by 120
Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages
Smythies, L. E., White, C. R., Maheshwari, A., Palgunachari, M. N., Anantharamaiah, G. M., Chaddha, M., Kurundkar, A. R., & Datta, G. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00467.2009 · Cited by 117
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Stein, E. A., Roth, E. M., Rhyne, J. M., Burgess, T., Kallend, D., & Robinson, J. G. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp601 · Cited by 109
Update on the use of fibrates: focus on bezafibrate
Goldenberg, I., Benderly, M., & Goldbourt, U. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.2008.04.01.131 · Cited by 107
Viswambharan, H., Ming, X.-F., Zhu, S., Hubsch, A., Lerch, P., Vergères, G., Rusconi, S., & Yang, Z. (2004) · Circulation Research · doi:10.1161/01.res.0000124302.20396.b7 · Cited by 104
Structure and Function of HDL Mimetics
Navab, M., Shechter, I., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J., & Fogelman, A. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.187518 · Cited by 104
Barter, P. J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.014 · Cited by 103
Lenten, B. J. V., Wagner, A. C., Navab, M., Anantharamaiah, G. M., Hama, S. Y., Reddy, S. T., & Fogelman, A. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700138-jlr200 · Cited by 103
Cannon, C. P., Dansky, H. M., Davidson, M. H., Gotto, A. M., Brinton, E. A., Gould, A. L., Stepanavage, M. E., Liu, S. X., Shah, S., Rubino, J., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.028 · Cited by 92
de Grooth, G. J., Smilde, T. J., van Wissen, S., Klerkx, A. H. E. M., Zwinderman, A. H., Fruchart, J., Kastelein, J. J. P., Stalenhoef, A. F. H., & Kuivenhoven, J. A. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.11.020 · Cited by 88
Nicotinic acid receptor subtypes and their ligands
Soudijn, W., van Wijngaarden, I., & IJzerman, A. P. (2007) · Medicinal Research Reviews · doi:10.1002/med.20102 · Cited by 88
Niacin: a re‐emerging pharmaceutical for the treatment of dyslipidaemia
Vosper, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00349.x · Cited by 81
Arca, M., Montali, A., Valiante, S., Campagna, F., Pigna, G., Paoletti, V., Antonini, R., Barillà, F., Tanzilli, G., Vestri, A., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.049 · Cited by 81
Influence of ApoA-I Structure on the ABCA1-mediated Efflux of Cellular Lipids
Vedhachalam, C., Liu, L., Nickel, M., Dhanasekaran, P., Anantharamaiah, G. M., Lund-Katz, S., Rothblat, G. H., & Phillips, M. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406924200 · Cited by 77
Briand, F., Naik, S. U., Fuki, I. V., Millar, J. S., Macphee, C. H., Walker, M., Billheimer, J. T., Rothblat, G. H., & Rader, D. J. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00098.x · Cited by 76
Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone
Shah, N. D., Montori, V. M., Krumholz, H. M., Tu, K., Alexander, G. C., & Jackevicius, C. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1011042 · Cited by 76
Imaging Biomarkers in Atherosclerosis Trials
Tardif, J., Lesage, F., Harel, F., Roméo, P., & Pressacco, J. (2011) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.110.962001 · Cited by 73
Franceschini, G., Sirtori, C. R., Bosisio, E., Gualandri, V., Orsini, G. B., Mogavero, A. M., & Capurso, A. (1985) · Atherosclerosis · doi:10.1016/0021-9150(85)90063-2 · Cited by 71
Berrougui, H., Loued, S., & Khalil, A. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.01.019 · Cited by 71
Athyros, V. G., Mikhailidis, D. P., Papageorgiou, A. A., Symeonidis, A. N., Mercouris, B. R., Pehlivanidis, A. N., Bouloukos, V. I., Elisaf, M., & for the GREACE Study Collaborative Group (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003421 · Cited by 66
Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice
Hernandez, M., Wright, S. D., & Cai, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.079 · Cited by 66
Streja, L., Packard, C. J., Shepherd, J., Cobbe, S. M., & Ford, I. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02599-7 · Cited by 66
Carson, S. D. (1981) · FEBS Letters · doi:10.1016/0014-5793(81)80422-x · Cited by 64
Farnier, M. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3390 · Cited by 63
Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein
Smith, J. D. (2010) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2010.08.007 · Cited by 62
Milionis, H., Moutzouri, Kei, & Elisaf (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59
Rosso, L. A. G., Benítez, M. B., Fornari, M. C., Berardi, V. E., Lynch, S., Schreier, L. E., Wikinski, R., Cuniberti, L. A., & Brites, F. D. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.007 · Cited by 57
Cho (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000322 · Cited by 49
Zadelaar, A. S. M., Boesten, L. S. M., Jukema, J. W., van Vlijmen, B. J. M., Kooistra, T., EMEIS, J. J., Lundholm, E., Camejo, G., & Havekes, L. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000242904.34700.66 · Cited by 48
Low high-density lipoprotein cholesterol: current status and future strategies for management
Singh, V. N., Sharma, R., Kumar, A., & DEEDWANIA, P. C. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5685 · Cited by 48
Jamróz-Wiśniewska, A., Wójcicka, G., Horoszewicz, K., & Bełtowski, J. (2007) · PubMed · Cited by 47
van der Hoorn, J., Lindén, D., Lindahl, U., Bekkers, M., Voskuilen, M., Nilsson, R. G., Oscarsson, J., Lindstedt, E., & Princen, H. M. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01168.x · Cited by 47
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels
Hausenloy, D. J., & Yellon, D. M. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32832ebfe7 · Cited by 46
Srivastava, R. A. K. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.033 · Cited by 46
Goldenberg, I., Benderly, M., Sidi, R., Boyko, V., Tenenbaum, A., Tanné, D., & Behar, S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.08.033 · Cited by 43
HANSEN, B. C., Tigno, X. T., Benardeau, A. M., Meyer, M., ŠEBÖKOVÁ, E., & Mizrahi, J. L. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-7 · Cited by 43
Wang, A., Prouty, C. P., Pelton, P. D., Yong, M., Demarest, K. T., Murray, W. V., & Kuo, G. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.096 · Cited by 43
LXRα regulates human CETP expression in vitro and in transgenic mice
Honzumi, S., Shima, A., Hiroshima, A., Koieyama, T., Ubukata, N., & Terasaka, N. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.025 · Cited by 42
An apolipoprotein A-I mimetic dose-dependently increases the formation of preβ1 HDL in human plasma
Troutt, J. S., Alborn, W. E., Mosior, M. K., Dai, J., Murphy, A., Beyer, T. P., Zhang, Y., Cao, G., & Konrad, R. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700385-jlr200 · Cited by 42
Asztalos, B. F., Demissie, S., Cupples, L. A., Collins, D. E., Cox, C. E., Horvath, K. V., Bloomfield, H. E., Robins, S. J., & Schaefer, E. J. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.018 · Cited by 42
van der Hoorn, J., Jukema, J. W., Havekes, L. M., Lundholm, E., Camejo, G., Rensen, P. C. N., & Princen, H. M. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00109.x · Cited by 40
Peng, D., Hiipakka, R. A., Xie, J., Dai, Q., Kokontis, J. M., Reardon, C. A., Getz, G. S., & Liao, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01202.x · Cited by 39
Kuo, G., Rano, T. A., Pelton, P. D., Demarest, K. T., Gibbs, A. C., Murray, W. V., Damiano, B. P., & Connelly, M. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801319d · Cited by 39
Mukherjee, R., Locke, K. T., Miao, B., Meyers, D. S., Monshizadegan, H., Zhang, R., Search, D. J., Grimm, D., Flynn, M. A., O’Malley, K. M., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143271 · Cited by 39
Is niacin ineffective? Or did AIM-HIGH miss its target?
Nicholls, S. J. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.11166 · Cited by 38
Tenenbaum, A., & Fisman, E. Z. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-24 · Cited by 36
The Triglyceride Connection in Atherosclerosis
Geurian, K., Pinson, J. B., & Weart, C. W. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202600913 · Cited by 35
Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier
Davidson, M. H., & Rosenson, R. S. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.020 · Cited by 34
Kim, M.-K., Chae, Y., Son, M. H., Kim, S. H., Kim, J. K., Moon, H. S., Park, C. S., Bae, M.-H., Kim, E., Han, T., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.066 · Cited by 31
Page, S. T., Krauss, R. M., Gross, C., Ishida, B. Y., Heinecke, J. W., Tang, C., Amory, J. K., Schaefer, P. M., Cox, C. J., Kane, J. P., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2813 · Cited by 28
Stannard, A. K., Khan, S., Graham, A., Owen, J. S., & Allen, S. P. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00444-5 · Cited by 28
Cui, H., Okuhira, K., Ohoka, N., Naito, M., Kagechika, H., Hirose, A., & Nishimaki‐Mogami, T. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.023 · Cited by 27
Wagner, J. D., Shadoan, M. K., Zhang, L., Ward, G. M., Royer, L. J., Kavanagh, K., Francone, O. L., Auerbach, B. J., & Harwood, H. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166736 · Cited by 27
Zhang, W.-J., Stocker, R., McCall, M. R., Forte, T. M., & Frei, B. B. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00247-2 · Cited by 22
Parhofer, K. G. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4502 · Cited by 21
Refocusing On Use of Cholesteryl Ester Transfer Protein Inhibitors
Kastelein, J. J. P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.08.013 · Cited by 20
Casimiro‐Garcia, A., Bigge, C. F., Davis, J. A., Padalino, T., Pulaski, J., Ohren, J. F., McConnell, P., Kane, C. D., Royer, L. J., Stevens, K. A., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.09.001 · Cited by 20
Kar, S., Patel, M. A., Tripathy, R. K., Bajaj, P., Suvarnakar, U. V., & Pande, A. H. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.05.002 · Cited by 18
Niacin's role in the statin era
Brooks, E. L., Kuvin, J., & Karas, R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.498818 · Cited by 17
van der Hoorn, J. W., Jukema, J. W., Havekes, L. M., Rensen, P. C. N., Lundholm, E., Camejo, G., & Princen, H. M. G. (2008) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(08)70837-7 · Cited by 15
Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL
Millar, J. S., Ikewaki, K., Bloedon, L. T., Wolfe, M. L., Szapary, P. O., & Rader, D. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p008136 · Cited by 15
Cited by
Gut microbiota and cardiovascular disease: opportunities and challenges
Kazemian, N., Mahmoudi, M., Halperin, F., Wu, J. C., & Pakpour, S. (2020) · Microbiome · doi:10.1186/s40168-020-00821-0 · Cited by 384
Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry
De Silva, D. D., Rapior, S., Sudarman, E., Stadler, M., Xu, J., Aisyah Alias, S., & Hyde, K. D. (2013) · Fungal Diversity · doi:10.1007/s13225-013-0265-2 · Cited by 271
Schwingshackl, L., & Hoffmann, G. (2013) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2013.07.010 · Cited by 218
Apolipoprotein A1 Forms 5/5 and 5/4 Antiparallel Dimers in Human High-density Lipoprotein
He, Y., Song, H. D., Anantharamaiah, G. M., Palgunachari, M. N., Bornfeldt, K. E., Segrest, J. P., & Heinecke, J. W. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000878 · Cited by 29
Centner, A. M., Shiel, E. A., Farra, W., Cannon, E. N., Landim-Vieira, M., Salazar, G., & Chelko, S. P. (2024) · Nutrients · doi:10.3390/nu16132087 · Cited by 8
“…including very low-and low-density lipoproteins (VLDLs and LDLs, respectively), are risk factors for cardiovascular disease (CVD), while high-density lipoprotein (HDL) cholesterol is regarded as heart-healthy, largely due to its ability to shuttle cholesterol for biliary excretion [17].”
Background
Metadata
- Authors
- Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-10-19
- Volume
- 167
- Issue
- 6
- Pages
- 1177-1194
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1535628640
- Cited by
- 292
- References
- 184
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.